Silexion Therapeutics Stock Soars 150% In Pre-Market On Announcement Of SIL204 Preclinical Data

(RTTNews) - Shares of Silexion Therapeutics Corp (SLXN) are soaring over 150 percent following the announcement of preclinical data on SIL204, demonstrating successful drug distribution to all primary sites of pancreatic cancer metastasis with measurable reductions in tumor.

In the pre-market hours, SLXN is trading at $11.53, up 156 percent, over the previous close of $5.06 on the Nasdaq.

The study, evaluating SIL204's biodistribution and therapeutic activity following subcutaneous administration, supported the company's approach of combining intratumoral delivery for primary tumors with systemic administration for disseminated disease.

Further, the company is conducting expanded tissue culture studies across multiple cancer types and KRAS mutations to further characterize SIL204's pan-KRAS potential, with results expected in the near future.

Moreover, the biotechnology company is on track to initiate Phase 2/3 clinical trials evaluating its dual-route administration approach in the first half of 2026, with regulatory submissions planned for fourth quarter of 2025 and first quarter of 2026.